Market Cap: $38.01B
NI
Natera, Inc.
NTRA
NASDAQ (NASDAQ Global Select)USD
Market Cap: $38.01B
Natera Inc. (Ticker: NTRA) announces a strategic partnership with Eledon Pharmaceuticals to integrate its Prospera test into a significant Phase 3 kidney transplant clinical trial. This collaboration…
Natera (Ticker: NTRA) has made significant strides in transplant diagnostics with the recent presentation of groundbreaking data at the 2026 American Transplant Congress. The new findings link the com…
Natera Inc. (Ticker: NTRA) is making waves in the medical diagnostics industry with groundbreaking data presented at the recent 2026 American Transplant Congress. The company's Prospera test, which pl…
Natera (Ticker: NTRA) is making strides in oncology with a new partnership aimed at revolutionizing personalized cancer care. The company, recognized for its advancements in genetic testing, has recen…
Natera (Ticker: NTRA) recently announces crucial advancements in its Panorama non-invasive prenatal test, addressing significant challenges in fetal fraction sampling. The latest enhancement of the Pa…
Natera, Inc., a pioneer in genetic testing, enhances its presence in transplant diagnostics at the recent International Society for Heart and Lung Transplantation (ISHLT) meeting. The company showcase…
Natera, Inc. showcases groundbreaking clinical findings for its Prospera transplant test at the 2026 ISHLT Annual Meeting, marking a significant milestone in the realm of transplant monitoring. These…
Natera Positions Itself as a Leader in Genetic Testing Innovation Natera, a prominent player in the genetic testing industry, is currently reinforcing its status through persistent innovation, particu…
Natera's Q4 Earnings Reflect Strong Growth and Innovation in Genetic Testing Natera (NASDAQ:NTRA) recently releases its Q4 earnings results, which shed light on the company’s notable growth and advanc…
Natera’s Growth Trajectory in Precision Medicine Highlighted in Q4 Earnings Natera, a prominent player in the genetic testing industry, reveals its Q4 earnings report, showcasing its significant progr…
Natera's Advancements in Genetic Testing Drive Q4 Performance Natera, a prominent player in the precision medicine sector, recently reveals its Q4 earnings, showcasing a significant trajectory in its…
Natera's Strategic Focus on AI Innovations Natera, a leader in genetic testing and diagnostics, operates within a rapidly evolving healthcare landscape that increasingly integrates artificial intellig…
Natera's Strategic Innovations in Genetic Testing Amid AI Advancements Natera, a leader in genetic testing and diagnostics, operates in an industry increasingly influenced by advancements in artificia…
Natera's Pioneering Research in Precision Medicine: Insights from the PALLAS Study Natera Inc. announces preliminary findings from its international randomized Phase 3 PALLAS study, marking a pivotal…
Natera Advances Precision Medicine with PALLAS Study Findings Natera Inc. announces preliminary findings from its international randomized Phase 3 PALLAS study, a significant milestone that underscore…
Natera's PALLAS Study: A Leap Towards Precision Medicine Natera Inc. recently announces preliminary findings from its international randomized Phase 3 PALLAS study, marking a significant milestone in…
Natera Expands Oncology Diagnostics Portfolio with Foresight Acquisition Natera, Inc. has made a significant move in the oncology diagnostics sector by acquiring Foresight Diagnostics for an upfront p…
Natera Expands Oncology Diagnostics Portfolio Through Foresight Acquisition Natera, Inc. announces a strategic acquisition of Foresight Diagnostics, a firm specializing in cancer diagnostics, for an u…
Natera’s Strategic Positioning in the Evolving Landscape of Technology and Healthcare Natera, a leader in genetic testing and diagnostics, finds itself at a pivotal moment as the intersection of techn…
Natera's Strategic Positioning in the Evolving Landscape of Genetic Testing Natera, a leader in prenatal and genetic testing, continues to solidify its position within the rapidly advancing field of p…
Natera's Strategic Focus on Genomic Innovation Natera, a leader in genetic testing and diagnostics, continues to solidify its position in the healthcare sector by enhancing its genomic technologies an…
Natera's Role in Advancing Genetic Testing Solutions Natera, a leader in genetic testing and diagnostics, continues to make significant strides in the healthcare industry. The company specializes in n…
Natera's Role in Advancing Precision Medicine Natera, a leading genetic testing and diagnostics company, continues to play a pivotal role in the evolving landscape of precision medicine. With its focu…
Natera's Role in the Evolving Diagnostics Landscape Natera, a leader in genetic testing and diagnostics, finds itself at the forefront of a rapidly changing healthcare environment. As the demand for n…
Natera Faces Varied Analyst Sentiment Amid Market Dynamics Natera, a leading player in the biotechnology sector, currently experiences a wide spectrum of analyst ratings that reflect mixed sentiments…
Natera: Navigating Diverse Analyst Sentiments in Biotechnology Natera, a prominent player in the biotechnology sector, finds itself at a crossroads as analysts present a mixed bag of opinions regardin…
Natera's Navigating Analyst Sentiment in a Dynamic Market Natera Inc., a prominent player in the biotechnology sector specializing in genetic testing and diagnostics, faces a complex landscape as eigh…
Natera Sees Shift in Investor Sentiment Amid Declining Short Interest Natera, a prominent player in the genetic testing industry, is witnessing a significant shift in investor sentiment as evidenced b…
Natera’s Genetic Testing Innovations Spark Diverging Analyst Opinions Natera, Inc., a leader in genetic testing, finds itself at the center of attention as financial analysts provide a spectrum of eva…
Natera’s Genetic Testing Innovations Under Scrutiny Natera, Inc. stands at a pivotal crossroads as six financial analysts provide a spectrum of evaluations regarding the company’s performance and futu…
Natera Under Scrutiny: Divergent Analyst Perspectives Shape Future Outlook Natera, Inc. (NTRA), a leader in genetic testing and diagnostics, is currently under the analytical lens of six financial exp…
Natera Faces Patent Challenges in Genetic Testing Landscape In a notable legal development, the District Court for the Middle District of North Carolina recently rules against Natera Inc. regarding it…
Natera Faces Legal Setback in Patent Dispute with NeoGenomics In a recent ruling by the District Court for the Middle District of North Carolina, Natera Inc. (NTRA) experiences a significant legal blo…
Natera's Focus on Genetic Testing Innovation Amid Market Developments Natera, a prominent player in the genetic testing industry, continues to advance its leadership position through a commitment to i…
Natera Focuses on Advancing Genetic Testing Solutions Amid Industry Developments Natera, a leader in genetic testing and diagnostics, continues to position itself at the forefront of innovation within…
Natera Faces Mixed Analyst Ratings Reflecting Industry Complexities In the latest quarter, Natera, a prominent player in the genetic testing and diagnostics industry, garners attention from five analy…
Natera's Analyst Ratings Reflect Market Complexities In the latest quarter, Natera (NTRA) garners attention as five analysts provide a spectrum of ratings, illustrating the mixed sentiment surrounding…
Natera's Strong Performance Amid Industry Volatility Natera, a leader in genetic testing and diagnostics, showcases robust growth as it surpasses Wall Street's revenue expectations in its latest earni…
Natera's Growth Trajectory: A Promising Outlook Amid Analyst Divergence In the latest quarter, Natera (NTRA) garners attention for exceeding Wall Street's revenue expectations, leading to an 11% surge…
Natera's Strategic Position in the Expanding Genetic Testing Market Natera, a prominent player in the genetic testing industry, is carving out a significant niche with its innovative cancer monitoring…
Natera Stakes Its Claim in the Genetic Testing Landscape Natera, a prominent player in the genetic testing sector, is carving out a significant position with its innovative cancer monitoring test, Sig…
Natera Advances Personalized Cancer Care with NCCN Guidelines Update Natera, Inc., a frontrunner in cell-free DNA and genetic testing, responds positively to the National Comprehensive Cancer Network…
Natera Expands Access to Fetal RhD Testing with New Coverage Policy Natera, Inc., a prominent player in the field of cell-free DNA and genetic testing, announces a significant development in prenatal…
Transforming Cancer Care: The Surge of Minimal Residual Disease Testing The minimal residual disease (MRD) testing market is poised for substantial growth, reflecting an evolving landscape in oncology…
Natera's Strategic Position in the Growing MRD Testing Market Natera operates in a pivotal segment of the healthcare industry, particularly in the realm of minimal residual disease (MRD) testing. Rece…
Natera Pioneers Advancements in Oncology Diagnostics at J.P. Morgan Healthcare Conference At the recently concluded 43rd annual J.P. Morgan Healthcare Conference, Natera, Inc. showcased its commitment…
Natera Advances Cancer Diagnostics with Innovative Assays Natera, Inc. makes significant strides in oncology diagnostics at the 43rd annual J.P. Morgan Healthcare Conference. CEO Steve Chapman shares…
Natera Reports Significant Growth in Genetic Testing Sector Natera, Inc., a prominent player in the field of cell-free DNA and genetic testing, announces remarkable preliminary results for the fourth…
Natera's Significant Growth in Genetic Testing and Oncology Services Natera, Inc., a prominent player in the field of cell-free DNA and genetic testing, showcases remarkable growth in its preliminary…
Natera Advances Personalized Cancer Treatment with SAGITTARIUS Trial Natera, Inc., a frontrunner in cell-free DNA and genetic testing, initiates the SAGITTARIUS clinical trial, a crucial development i…